Vor Biopharma is a US company working on R&D for innovative cancer treatment using hematopoietic stem cells (HSC's). This technology enables selectively affecting cancer cells without touching the healthy ones. Overall, the company has three R&D programs, one being at stage 1/2 of the clinical trials.
Since its inception, the company raised $152M, the major stakeholders being RA Capital Healthcare Fund, 5AM Ventures VI, PureTech Health LLC, FMR, and others.
Vor Biopharma IPO: Key Facts:
● Yield Potential: 34%
● IPO Date: February 4
● Exchange: NASDAQ (trading as VOR)
● IPO Size: $150M
● Starting Price: $16.00 to $18.00
● Underwriters: Goldman Sachs, Evercore ISI, Barclays, Stifel
● Market Cap: $588M
● Earnings in 9 mon. 2020: 0
● EBIT in 9 mon. 2020: -$28M
● Net Profit in 9 mon. 2020: -$28M
● Net Debt in 9 mon. 2020: 0
You can find Vor Biopharma Security Security Issue Memo on the SEC website.
You can apply to trade Vor Biopharma IPO before February 3, 6:00 pm UTC+2. In order to trade, you need an investment account with Freedom Finance. The minimum investment amount is $2,000, the lock up being 93 days.
As there is a huge number of people willing to invest into IPO's, you may receive shares worth a smaller amount than you specified in your order. Learn how to increase your allocation and get more IPO shares here.